Top Tweets for #TimeToX

over 1 year ago

@ClarkHenegan @MASCC_JSCC @EnriqueSoto8 @OncoAlert @PallOncCoP Agreed would love to see a bigger trial looking at #GeriOnc multi-institutional and we all agree that #TimeTox has a major impact on this population. Firm advocate that #telehealth reduces #TimeTox and extends resources @OncoAlert https://t.co/0apbfamtwC

OncoAlert

@OncoAlert

over 1 year ago

Oncology HERE & NOW Webcast/Podcast Now Out JOIN Faulty 🚨 @realbowtiedoc 🇺🇸& @crisbergerot 🇧🇷 as they dive into #SupportiveCare , the future of #Telemedicine and much more! LINKS: https://t.co/FP3Z1RXdYy Apple Podcast🍏 https://t.co/m37dP2v6jj Spotify Podcast🎙️ https://t.co/QTzYsLUnJ4 Amazon Podcast🎙️ https://t.co/2vJxOboRHk @matteolambe @Icro_Meattini @maryam_lustberg @kevinpunie @montypal @PGrivasMDPhD @NazliDizman @CathyEngMD @ARosen380 @BenWestphalen @DrYukselUrun @agz_eriksson @helitropen @DarcyBurbage @AndreasC466 @IshwariaMD @WilliamDale_MD @oncoclinicas @RyanNipp @CancerCareMASCC @jgong15 @OncBrothers @shilpaonc @neerajaiims @apolo_andrea @ReginaBarCar @JGeriOnc @rayychan #OncoAlertAF @nataliagandur @acampsmalea @BiagioRicciutMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Dr_Ivanoncologo @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @NiuSanford

2

38

16

2

26K

0

7

4

0

2K

over 1 year ago

#SuppOnc and #GeriOnc study in @MASCC_JSCC #OlderAdults ≥65 with #cancer have: ~21% of days in healthcare settings 🏥 ⬆️#TimeTox ⏲️if 💉☢️ or frail. Informed consent means #Time is in the ⚖️ 🔗: https://t.co/BRCnsnhQKi @EnriqueSoto8 @OncoAlert🚨 @PallOncCoP #OncoAlertAF @yekeduz_emre @FadiHaddad_MD @Abdallah81MD @Erman_Akkus @bavilima @acampsmalea @DrFMartinelli @lungoncdoc @Dr_Ivanoncologo @orellanauro @FernandoOnco @Lucarecco @HHorinouchi @ElisaAgostinett @to_be_elizabeth @BiagioRicciutMD @nataliagandur @GaiaGriguolo @JankovicK @weoncologists @OncoReporte

1

17

9

0

1K

about 2 years ago

Dr. @JCBaltussen and colleagues published in @MASCC_JSCC 158 🇲🇽older adults #GeriOnc: 21% of days involved healthcare contact (1/5th of life on tx‼️) #Timetox was higher for those receiving ☢️ or💉or #frail patients. We MUST include #Timetox in #InformedConsent 🔗: https://t.co/BRCnsnhQKi #pallonc #supponc @PallOncCoP @OncoAlert🚨 @EnriqueSoto8 #OncoAlertAF @yekeduz_emre @FadiHaddad_MD @Abdallah81MD @Erman_Akkus @Abdallah81MD @bavilima @acampsmalea @DrFMartinelli @lungoncdoc @Dr_Ivanoncologo @orellanauro @FernandoOnco @Lucarecco @HHorinouchi @ElisaAgostinett @to_be_elizabeth @BiagioRicciutMD @nataliagandur

realbowtiedoc's tweet photo. Dr. @JCBaltussen and colleagues published in @MASCC_JSCC

158 🇲🇽older adults #GeriOnc:
21% of days involved healthcare contact (1/5th of life on tx‼️)
#Timetox was higher for those receiving ☢️ or💉or #frail patients.

We MUST include #Timetox in #InformedConsent

🔗: https://t.co/BRCnsnhQKi

#pallonc #supponc @PallOncCoP @OncoAlert🚨 @EnriqueSoto8

#OncoAlertAF
@yekeduz_emre
@FadiHaddad_MD
@Abdallah81MD
@Erman_Akkus
@Abdallah81MD
@bavilima
@acampsmalea
@DrFMartinelli
@lungoncdoc
@Dr_Ivanoncologo
@orellanauro
@FernandoOnco
@Lucarecco
@HHorinouchi
@ElisaAgostinett
@to_be_elizabeth
@BiagioRicciutMD
@nataliagandur

0

20

14

0

2K

The Oncologist @OncJournal

about 2 years ago

Poster Bd D6: Study reveals gap in time toxicity for stage III/IV NSCLC Similar contact days as those in routine practice but ⬆️ overall survival & initiated treatments sooner! More lab tests and treatment visits. Need to ⬇️ #timetox #ASCOQLTY14 @guptaarjun90 By @crisbergerot

realbowtiedoc's tweet photo. Poster Bd D6: Study reveals gap in time toxicity for stage III/IV NSCLC
Similar contact days as those in routine practice but ⬆️ overall survival & initiated treatments sooner!
More lab tests and treatment visits. Need to ⬇️ #timetox #ASCOQLTY14 @guptaarjun90
By @crisbergerot https://t.co/8SJ3n6r6aF

0

8

3

0

369

about 2 years ago

Dr @guptaarjun90 et al described that nearly half of advanced cancer patients consider #timetox when making treatment decisions. Preference for treatments with ⬆️PFS and declining those 🚫OS benefits #pallonc #supponc https://t.co/V4PuCbTPDI

OncJournal's tweet photo. Dr @guptaarjun90 et al described that nearly half of advanced cancer patients consider #timetox when making treatment decisions. Preference for treatments with ⬆️PFS and declining those 🚫OS benefits #pallonc #supponc
https://t.co/V4PuCbTPDI https://t.co/aEvgESjugI

1

11

3

0

2K

almost 3 years ago

I'm slipped in a subtle reference to time toxicity in this discussion about KarMMa-3 and BCMA CAR-T in #MMsm 👍🏻 Much longer PFS, dramatically better QOL & symptoms, and less #timetox with both ide-cel & cilta-cel: keeping my 🤞 for expanded approval! https://t.co/nQkyUu4pE4

RahulBanerjeeMD's tweet photo. I'm slipped in a subtle reference to time toxicity in this discussion about KarMMa-3 and BCMA CAR-T in #MMsm 👍🏻

Much longer PFS, dramatically better QOL & symptoms, and less #timetox with both ide-cel & cilta-cel: keeping my 🤞 for expanded approval!

https://t.co/nQkyUu4pE4 https://t.co/47AUgfr0cv

1

9

2

1

2K

almost 3 years ago

10/ #ASH23 bottom line: time toxicity is an issue across the spectrum of hematology, and smart-sizing care models is a priority for our patients! cc @guptaarjun90 @erin_bange @NicoleKuderer @fumikochino and others leading the #timetox charge in solid oncology. More to come!

1

2

0

482

almost 3 years ago

7/ #ASH23 #4571 (Masarova et al): #timetox of transfusions in myelofibrosis. I chose this piece for its very granular analysis: not just days with transfusions, but estimated hours spent including transit and waiting for T&S. This is what pts experience but we don't see!

RahulBanerjeeMD's tweet photo. 7/ #ASH23 #4571 (Masarova et al):

#timetox of transfusions in myelofibrosis.

I chose this piece for its very granular analysis: not just days with transfusions, but estimated hours spent including transit and waiting for T&S.

This is what pts experience but we don't see! https://t.co/rdlpeCwCl7

1

2

0

544

almost 3 years ago

1/ #ASH23 isn't over yet! Come join us tomorrow for our virtual poster walk about time toxicity in hematology. What: Strategies across heme to ⬆️ time at home. Who: All of you! Where: Virtual platform When: Tomorrow (Dec 14), 5pm PST What #timetox research will we hear about?

RahulBanerjeeMD's tweet photo. 1/ #ASH23 isn't over yet! Come join us tomorrow for our virtual poster walk about time toxicity in hematology.

What: Strategies across heme to ⬆️ time at home.
Who: All of you!
Where: Virtual platform
When: Tomorrow (Dec 14), 5pm PST

What #timetox research will we hear about?

2

38

14

2

12K

almost 3 years ago

#ASH23 all-star fellow @DimaDanai presenting multicenter RWE #MMsm myeloma data with teclistamab! Note the condensed schedule (Days 1,3,5 dosing) which is what most of us have started using already to lower #timetox and healthcare utilization.

RahulBanerjeeMD's tweet photo. #ASH23 all-star fellow @DimaDanai presenting multicenter RWE #MMsm myeloma data with teclistamab!

Note the condensed schedule (Days 1,3,5 dosing) which is what most of us have started using already to lower #timetox and healthcare utilization. https://t.co/KHvAnuip6Y

2

38

10

5

5K

Fred Hutch Cancer Center @fredhutch

almost 3 years ago · San Diego

🥹 I’ll hang this on my fridge - thanks @fredhutch for the kind words and amazing support of my #ASH23 research!! #downwithdex, #timetox, & #VelcadeReductionService. If it can improve the patient experience in #MMsm myeloma, and if it can be made into a hashtag, count me in!

almost 3 years ago

At #ASH23, @RahulBanerjeeMD will present the results of several studies related to #multiplemyeloma treatment, sharing insights on reducing financial toxicity, time toxicity and side effects of treatment. https://t.co/oECB9JWnLB #MMsm

0

23

4

0

4K

0

20

1

0

2K

Debra Lundquist, PhD, RN @LundquistDebra

almost 3 years ago

Thrilled to share the findings of our research with patients on Phase I clinical trials @ASCOQLTY23 #PallCare #FinTox #TimeTox Grateful for the amazing mentorship or @RyanNipp!!

LundquistDebra's tweet photo. Thrilled to share the findings of our research with patients on Phase I clinical trials @ASCOQLTY23
#PallCare #FinTox #TimeTox
Grateful for the amazing mentorship or @RyanNipp!! https://t.co/Ew0vTZR2N9

0

18

7

0

1K